Why Oscar Health, Inc. (OSCR) Outpaced the Stock Market Today

Oscar Health (OSCR) saw a 1.76% gain in its latest trading session, outperforming the S&P 500, yet its stock has declined 30.66% over the past month, significantly underperforming its sector and broader market. Ahead of its August 6, 2025 earnings, analysts project Q3 revenue growth of 30.15% to $2.89 billion, but anticipate a 395% EPS decline to -$0.59, with full-year EPS expected to drop 780%. This negative earnings outlook is underscored by a 211.41% downward revision in consensus EPS estimates over the past month, leading to a Zacks Rank of #4 (Sell) and placing its multi-line insurance industry in the bottom 36% of all sectors.

Analysis

Despite a minor single-day gain of 1.76%, Oscar Health (OSCR) has demonstrated significant weakness, with its stock plummeting 30.66% over the past month, severely underperforming both the Finance sector and the S&P 500. The core issue driving this negative sentiment is a stark divergence between top-line growth and bottom-line profitability forecasts. While analysts project robust revenue growth of 30.15% for the upcoming quarter and 29.34% for the full year, this is completely overshadowed by a catastrophic earnings outlook. The consensus estimate for the next quarter's EPS is -$0.59, a 395% year-over-year decline, with the full-year EPS expected to fall 780%. This deteriorating outlook is validated by a 211.41% downward revision in the Zacks Consensus EPS estimate over the last month, a key factor contributing to the stock's Zacks Rank of #4 (Sell). Furthermore, the company operates within the beleaguered Insurance - Multi line industry, which ranks in the bottom 36% of all industries, suggesting broader sector headwinds may be compounding company-specific challenges.

Key Decisions for Investors

• Investors should treat the stock with extreme caution, as the projected 30% revenue growth is substantially outweighed by the severe deterioration in earnings forecasts and the formal Zacks #4 (Sell) rating.
• The upcoming August 6, 2025, earnings release is a critical catalyst; focus should be on management's guidance regarding a path to profitability, as the current disconnect between revenue growth and earnings is unsustainable.
• Given the significant 211.41% downward revision in consensus EPS estimates, any existing bullish thesis should be rigorously re-evaluated, as the fundamental outlook has materially worsened over the past month.